MAXHEALTH
Max Healthcare
Each stock's 10,000-path forecast, rendered as light.
Max Healthcare (MAXHEALTH) Stock Analysis & Case Study
Is MAXHEALTH a good buy? The data-driven verdict.
Max Healthcare (MAXHEALTH) trades at ₹1,095,on the numbers it tread carefully, a Downstox Snapshot Score of 41/100.
On the numbers, Max Healthcare (MAXHEALTH) tread carefully, a Downstox Snapshot Score of 41/100, weighing expensive at 71.7× earnings, ROE of 14.8%, a 57% model probability of trading higher in a year. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027–2031.
Last updated . Data snapshot for research, not investment advice.
MAXHEALTH fundamentals at a glance, PE, PB, ROE, ROCE, market cap, dividend yield
Is MAXHEALTH overvalued? MAXHEALTH P/E vs its Healthcare
MAXHEALTH's P/E of 71.7× sits above the Healthcare peer median of 17.9×, so on earnings it screens richer than peers, while its 0.14% dividend yield is below the peer median of 0.81%.
MAXHEALTH share price target 2027, 2028, 2029, 2030, 2031, a probability view
Unlike a single guessed number, this is a probability-weighted range from a 10,000-path Monte-Carlo simulation on 2.0y of MAXHEALTH history (10%/yr drift, 32%/yr volatility).
| Year | Low (P10) | Median target (P50) | High (P90) | Upside vs today |
|---|---|---|---|---|
| MAXHEALTH 2027 | ₹765 | ₹1,153 | ₹1,727 | +5% |
| MAXHEALTH 2028 | ₹681 | ₹1,212 | ₹2,130 | +11% |
| MAXHEALTH 2029 | ₹627 | ₹1,276 | ₹2,547 | +17% |
| MAXHEALTH 2030 | ₹592 | ₹1,338 | ₹2,993 | +22% |
| MAXHEALTH 2031 | ₹564 | ₹1,411 | ₹3,471 | +29% |
Median (P50) is the central estimate; the P10–P90 band is the 80% confidence range. Probabilities, not promises.
What is the probability MAXHEALTH goes up, or doubles?
The bull case for MAXHEALTH
- A healthy 14.8% return on equity.
- Upside scenario: the model's optimistic (P90) 3-year path reaches ₹2,547.
The bear case & risks
- A rich 71.7× P/E leaves a thin margin of safety if growth slows.
- A steep 9.9× price-to-book means most of the value is intangible/expectations, not assets on the books.
- Downside scenario: the model's pessimistic (P10) 3-year path falls to ₹627.
MAXHEALTH volatility & expected range, how bumpy is the ride?
Over the last 2.0 years MAXHEALTH compounded at 10%/year with annualized volatility of 32%. That volatility implies a 1-year 80% range of ₹765–₹1,727, the honest backbone behind any single price target.
MAXHEALTH price forecast, the full 60-month probability fan
MAXHEALTH price probability fan
Each band shows where 10,000 simulated paths land. The wider the fan, the more uncertainty.
Probability of key outcomes
What are the odds MAXHEALTH hits common targets within the simulated horizon?
Full multi-horizon detail on the MAXHEALTH price target & forecast page.
MAXHEALTH Piotroski F-Score: 4/9, how financially strong is it?
The Piotroski F-Score grades financial strength on nine profitability, leverage and efficiency checks. MAXHEALTH scores 4/9,mixed financial health.
MAXHEALTH MTF margin & leverage, Upstox, Zerodha, Groww, Dhan
Margin Trading Facility lets you buy MAXHEALTH with part of the capital. Lower margin % = higher leverage. Rates compared across brokers (no competitor publishes this):
| Broker | Margin required | Approx. leverage |
|---|---|---|
| Upstox | 29.6% | 3.4× |
| Zerodha | 25.2% | 4.0× |
| DhanCHEAPEST | 24.0% | 4.2× |
Compare every broker on the MAXHEALTH MTF page.
MAXHEALTH vs peers,Healthcare comparison
About Max Healthcare: sector, index & market-cap context
Max Healthcare (MAXHEALTH) is a large-cap NSE-listed company in the Healthcare sector, and a constituent of the Nifty 50 index group, with a market capitalisation of ₹1.06L Cr. See more Nifty 50 stocks.
How the MAXHEALTH Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of Max Healthcare's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
MAXHEALTH analysis, FAQs
Is Max Healthcare (MAXHEALTH) a good buy?
On the numbers, Max Healthcare (MAXHEALTH) tread carefully, a Downstox Snapshot Score of 41/100, weighing expensive at 71.7× earnings, ROE of 14.8%, a 57% model probability of trading higher in a year. This is a data snapshot for research, not investment advice.
Is MAXHEALTH overvalued or undervalued?
MAXHEALTH trades at 71.7× earnings versus a peer median of 17.9×, so it screens richer than its Healthcare peers.
What is the MAXHEALTH share price target for 2031?
MAXHEALTH's probability-weighted 2031 median target is ₹1,411, with an 80% range of ₹564–₹3,471 (10,000-path Monte-Carlo).
What is the probability MAXHEALTH doubles in 5 years?
The modelled probability of MAXHEALTH reaching ₹2,190 (2×) within 5 years is 26%.
What is the bull case for MAXHEALTH?
A healthy 14.8% return on equity.
What are the risks in MAXHEALTH?
A rich 71.7× P/E leaves a thin margin of safety if growth slows. A steep 9.9× price-to-book means most of the value is intangible/expectations, not assets on the books.